Similar articles

• Ninety day subchronic toxicity of N-2-fluorenylacetamide (2-FAA) in C57BL-6j and BALB-cStCr1BR mice.

  Haley TJ, Schieferstein G, Harmon JR, Dooley KL, Jaques WE, Frith C, Farmer JH. Haley TJ, et al. Proc Soc Exp Biol Med. 1974 Jun;146(2):648-51. Proc Soc Exp Biol Med. 1974. PMID: 4834472 No abstract available.
• Dose-response hyperplasia and neoplasia from feeding N-2-fluorenylacetamide (2-FAA) to BALB/c mice for varying time intervals.

  Haley TJ, Farmer J, Jaques WE, Frith C, Sprowls RW, Schieferstein G. Haley TJ, et al. Proc Soc Exp Biol Med. 1976 Jun;152(2):156-9. doi: 10.3181/00379727-152-39350. Proc Soc Exp Biol Med. 1976. PMID: 935178
• Early elevation of alpha 1-fetoprotein in N-2-fluorenylacetamide hepatocarcinogenesis.

  Becker FF, Sell S. Becker FF, et al. Cancer Res. 1974 Oct;34(10):2489-94. Cancer Res. 1974. PMID: 4412886 No abstract available.
• Effect of acetanilide and p-hydroxyacetanilide on the carcinogenicity of N-2-fluorenylacetamide and N-hydroxy-N-2-fluorenylacetamide in mice, hamsters, and female rats.

  Weisburger JH, Weisburger EK, Madison RM, Wenk ML, Klein DS. Weisburger JH, et al. J Natl Cancer Inst. 1973 Jul;51(1):235-40. doi: 10.1093/jnci/51.1.235. J Natl Cancer Inst. 1973. PMID: 4720874 No abstract available.
• The biology of bladder cancer.

  Cooper EH. Cooper EH. Ann R Coll Surg Engl. 1972 Jul;51(1):1-16. Ann R Coll Surg Engl. 1972. PMID: 5043669 Free PMC article. No abstract available.